AbCellera Biologics (NASDAQ:ABCL) Stock Gets Price Target Increase from Piper Sandler

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) had its price target lifted by analysts at Piper Sandler from $12.00 to $20.00 in a report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler‘s target price would indicate a potential upside of 74.06% from the stock’s previous close.

ABCL has been the subject of a number of other research reports. JPMorgan Chase & Co. began coverage on AbCellera Biologics in a report on Tuesday, September 29th. They issued an “overweight” rating and a $17.00 price target for the company. Cantor Fitzgerald lifted their target price on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Thursday, October 15th. Stifel Nicolaus upped their target price on AbCellera Biologics from $9.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Finally, StoneX increased their price target on AbCellera Biologics from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.55.

View Our Latest Stock Analysis on ABCL

AbCellera Biologics Price Performance

AbCellera Biologics stock opened at $11.49 on Monday. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of -23.94 and a beta of 1.59. AbCellera Biologics has a 1 year low of $2.74 and a 1 year high of $15.02. The firm has a 50-day moving average of $12.34 and a two-hundred day moving average of $7.23.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. The business had revenue of $10.64 million for the quarter, compared to the consensus estimate of $8.42 million. AbCellera Biologics had a negative net margin of 218.54% and a negative return on equity of 15.35%. During the same period in the prior year, the firm earned ($0.19) EPS. Research analysts expect that AbCellera Biologics will post -0.65 earnings per share for the current year.

Insider Activity

In other AbCellera Biologics news, major shareholder Holdings Ltd. Thermopylae acquired 60,565 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were bought at an average cost of $11.54 per share, with a total value of $698,920.10. Following the completion of the acquisition, the insider directly owned 56,194,662 shares in the company, valued at $648,486,399.48. This represents a 0.11% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 28.40% of the company’s stock.

Institutional Trading of AbCellera Biologics

Several hedge funds and other institutional investors have recently bought and sold shares of ABCL. Cetera Investment Advisers purchased a new position in shares of AbCellera Biologics in the 3rd quarter valued at $163,000. FORA Capital LLC bought a new stake in AbCellera Biologics during the third quarter valued at about $254,000. Marshall Wace LLP boosted its position in AbCellera Biologics by 370.9% during the third quarter. Marshall Wace LLP now owns 8,958,273 shares of the company’s stock valued at $130,701,000 after purchasing an additional 7,056,082 shares in the last quarter. Caxton Associates LLP grew its stake in AbCellera Biologics by 144.7% in the third quarter. Caxton Associates LLP now owns 162,431 shares of the company’s stock valued at $2,370,000 after purchasing an additional 96,053 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new position in AbCellera Biologics in the third quarter valued at about $2,059,000. Institutional investors own 61.42% of the company’s stock.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

See Also

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.